Feedback PLC Feedback Medical CEO appointed Feedback plc CEO (5008V)
09 April 2019 - 8:00AM
UK Regulatory
TIDMFDBK
RNS Number : 5008V
Feedback PLC
09 April 2019
Feedback plc
CEO of Feedback Medical appointed CEO of Feedback plc
Cambridge, UK, 9 April 2019 - Feedback plc (AIM: FDBK,
"Feedback", or the "Company"), the specialist medical imaging
technology company, has appointed Dr Tom Oakley as its Chief
Executive Officer with immediate effect. This follows his
appointment as CEO of its operating subsidiary, Feedback Medical
Ltd on 14 February 2019. Dr Alastair Riddell will resume the role
of Non-Executive Chairman of Feedback, the position he held prior
to becoming Executive Chairman in July 2018.
As announced on 14 February 2019, Dr Oakley is a qualified
medical doctor with experience in radiology. He has significant
expertise in successfully launching healthcare products and helping
small companies to realise and grow their market potential,
particularly within the digital healthcare space. He also brings
strong clinical and academic experience to the Company, having been
an NHS England Clinical Entrepreneur Fellow since 2016. He received
his Bachelor of Medicine with distinction from the University of
Southampton.
Tom Oakley, CEO of Feedback plc, said:
"I look forward to taking on this expanded role. Since joining
Feedback Medical, I have seen first-hand the potential within the
Company's innovative technology. I plan to complete a full review
of the business over the coming weeks, to develop a strategy which
will maximise Feedback's market position, identify growth areas and
review new potential market areas within digital imaging."
Alastair Riddell, Non-Executive Chairman of Feedback plc,
said:
"Tom is already making an impact on the Company and we welcome
him stepping up to become CEO of Feedback plc. As an able and
ambitious entrepreneurial radiology doctor with a proven track
record in developing innovative medical products, he understands
the technology and is well placed to drive the Company forward,
towards market expansion."
Option Grant
In conjunction with his appointment, Tom Oakley has today been
granted 9,332,081 options over new ordinary shares in the Company
("Options") (representing approximately 2.5 per cent. of the
Company's issued share capital) pursuant to the Company's Employee
Share Scheme. The Options have an exercise price of 1.09 pence per
Option and are exercisable at any time up to the tenth anniversary
of the grant.
The FCA notification in respect of the Option grant, made in
accordance with the requirements of the EU Market Abuse Regulation,
is appended below.
AIM Rules Disclosures
Thomas James Oakley, aged 31, is or has been during the last
five years, a director or partner of the following companies and
partnerships:
Current directorships/partnerships Past directorships/partnerships
* Innovation Doctor Limited * Healthtech Check Ltd
* Princes Castle Court Management Company Limited
* Oakley Concepts Ltd
* Locorum LLP
There is no further information required to be disclosed
pursuant to Schedule 2(g) of the AIM Rules.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Thomas Oakley
-------------------------- -----------------------------------------
2 Reason for the notification
---------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- -----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name Feedback plc
-------------------------- -----------------------------------------
b) LEI 213800UGOF2GT2U2RV90
-------------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------
a) Description of the Options over ordinary shares of 0.25p
financial instrument, each in Feedback plc
type of instrument
Identification code Identification code (ISIN) for Feedback
plc ordinary shares:
GB0003340550
-------------------------- -----------------------------------------
b) Nature of the transaction Grant of Options
-------------------------- -----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Exercise price
of 1.09p 9,332,081
----------
-------------------------- -----------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- -----------------------------------------
e) Date of the transaction 9 April 2019
-------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- -----------------------------------------
Enquiries:
Feedback plc
Tom Oakley, CEO +44 (0)1954 718072
Lindsay Melvin, CFO IR@fbk.com
Allenby Capital Limited (Nominated Adviser)
David Worlidge / Asha Chotai +44 (0)20 3328 5656
Peterhouse Corporate Finance Ltd (Joint Broker)
Lucy Williams / Duncan Vasey +44 (0)20 7469 0936
Stanford Capital Partners Limited (Joint
Broker)
Patrick Claridge / John Howes +44 20 3815 8880
Instinctif Partners +44 (0)20 7457 2020
Rozi Morris/ Deborah Bell/ Phillip Marriage feedbackplc@instinctif.com
About Feedback plc
Feedback plc (AIM: FDBK) is a specialist medical imaging
technology company providing innovative software and systems,
through its fully-owned trading subsidiary, Feedback Medical
Limited. Its products advance the work of radiologists, clinicians
and medical researchers by improving workflows and giving unique
insights into diseases, particularly cancer. Feedback Medical works
with customers globally from headquarters in the internationally
renowned scientific hub of Cambridge, UK. Its proprietary
technologies are TexRAD(R) , the quantitative texture analysis tool
and Cadran, a picture archiving communication system (PACS). For
more information, see www.fbkmed.com/plc-landing-page
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUWRBRKUASRAR
(END) Dow Jones Newswires
April 09, 2019 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024